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Abstract. Silicon-based nanoparticles are ideally suited for use as biomedical imaging agents due to their
biocompatibility, biodegradability, and simple surface chemistry that facilitates drug loading and targeting.
A method of hyperpolarizing silicon particles using dynamic nuclear polarization, which increases magnetic
resonance imaging signals by several orders-of-magnitude through enhanced nuclear spin alignment, has
recently been developed to allow silicon particles to function as contrast agents for in vivo magnetic resonance
imaging. The enhanced spin polarization of silicon lasts significantly longer than other hyperpolarized agents
(tens of minutes, whereas <1 min for other species at room temperature), allowing a wide range of potential
applications. We report our recent characterizations of hyperpolarized silicon particles, with the ultimate goal of
targeted, noninvasive, and nonradioactive molecular imaging of various cancer systems. A variety of particle
sizes (20 nm to 2 μm) were found to have hyperpolarized relaxation times ranging from ∼10 to 50 min. The
addition of various functional groups to the particle surface had no effect on the hyperpolarization buildup or
decay rates and allowed in vivo imaging over long time scales. Additional in vivo studies examined a variety
of particle administration routes in mice, including intraperitoneal injection, rectal enema, and oral gavage. © 2016
Society of Photo-Optical Instrumentation Engineers (SPIE) [DOI: 10.1117/1.JMI.3.3.036001]
Keywords: hyperpolarization; magnetic resonance imaging; silicon nanoparticles; molecular imaging.
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1 Introduction
1.1 Silicon Particles
Shaped particles consisting of elemental silicon or silicon diox-
ide (silica) in the nanometer- to micrometer-size scale are receiv-
ing heightened interest for medical applications, including drug
delivery and sensing,1 due to their low cost and lack of toxicity
for both the initial particles and their biodegradable downstream
products.2 Fluorescently tagged silicon particles have been
used to track living cells after uptake into the cytoplasm3
while naturally luminescent silicon nanoparticles (<10 nm) have
been applied in tracking pancreatic cancer cells in vitro.4
Furthermore, commercially available particles are also under-
going clinical trials for slow release drug delivery in the treat-
ment of pancreatic cancer.5 Because 29Si (nuclear spin: 1/2;
natural abundance: ∼4.6%) is detectable using magnetic reso-
nance imaging (MRI) or spectroscopy (MRS), developing sili-
con-based nanomaterials for MR studies may prove beneficial.
29Si MRI provides positive-contrast, background-free signals
that are within the frequency range of most broadband MR scan-
ners that are capable of detecting 13C signals. Silicon particles
ranging in size, porosity, purity, and crystallinity are commer-
cially available and cost-effective, and the field of silicon nano-
materials can benefit from developmental interests from the
semiconductor industry. The simple surface chemistry of silicon
particles is amenable to the addition of targeting agents
and therapeutic drugs—furthering their application to the
biomedical community—and small particles (<100 nm) have
increased circulation times in the vasculature (compared to
larger particles, which are more likely to be trapped by the
reticuloendothelial system).6
1.2 Hyperpolarized Magnetic Resonance
MRI and MRS measure the interactions of nuclear spins with
radiofrequency waves inside of a strong magnetic field. Due to
the small energetic differences in nuclear spin levels compared
to thermal energy, and the fact that the spins populating these
energy levels are oppositely aligned, the majority of the
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available magnetization is cancelled, leaving only a miniscule
number of nuclear spins to contribute to MR signals. This pop-
ulation difference, termed “polarization” (P), is typically on the
order of 10−5 to 10−6 at thermal equilibrium, and it is the pri-
mary reason for the relatively low detection sensitivity of MR-
based techniques. Clinical MR studies focus on 1H spins
because they possess the highest gyromagnetic ratio (γ)—pro-
viding more signal per spin, near-unity isotopic abundance, and
are highly prevalent in vivo. Aside from 19F,7 most other MR-
active species (including 29Si) have orders-of-magnitude lower
detection sensitivity compared to 1H due to lower γ and isotopic
abundance, limiting their feasibility for study in clinical settings.
One way to overcome the sensitivity challenge is through
“hyperpolarization” (HP), which refers to a collection of meth-
ods that temporarily boost MR signal intensities by redistribut-
ing the population of nuclear spins so that most occupy the same
energy level—allowing the spins to constructively contribute to
enhancing MR signals as opposed to destructively canceling
each other’s effect. This process typically uses magnetic fields,
low temperatures, and/or electromagnetic radiation to manipu-
late the nuclear spin population. Most hyperpolarization meth-
ods will highly spin-polarize an electron bath to near unity, then
transfer this spin polarization to nearby nuclear spins through
dipolar interactions. The result is an increase in detection sen-
sitivity by four to five orders-of-magnitude, allowing the study
of “nonconventional” nuclei for molecular and metabolic imag-
ing studies. Some of these include monitoring the metabolic
conversion of HP 13C-pyruvate to lactate and alanine to
probe cellular metabolic pathways8 in the field of cancer
detection,9 as well as lung space imaging using HP 3He and
129Xe in patients with chronic obstructive pulmonary disease
or asthma.10
1.3 Solid-State Dynamic Nuclear Polarization of
Silicon
A method of hyperpolarizing silicon micro- and nanoparticles11
using solid-state dynamic nuclear polarization (DNP) has
recently been developed12 and shown viable for in vivo imaging
studies13 in mice. In this method, low temperatures (<4 K) and
high magnetic fields (∼3 T) are used to spin-polarize an ensem-
ble of electrons. Then, this polarization is transferred to nearby
nuclei through microwave-mediated dipolar spin-flips; this
process takes place on the surface of the silicon particles,
which contain naturally occurring oxidation defects. Because
of this, the silicon particles do not require the addition of an
exogenous radical source of free electrons,14 which is needed
for most other nuclear species polarized by conventional
DNP (such as 13C-labeled metabolites). The polarization is
then spread into the core of the particle via nuclear spin
diffusion.12 Because the core of the particle is protected from
exposure to depolarizing paramagnetic agents, the enhanced
polarization is retained for tens of minutes—significantly longer
than most other hyperpolarized species, which typically lose
their signal enhancement in tens of seconds15 in vivo. This
increased hyperpolarized relaxation time (HP T1) holds true
even under physiological conditions and creates an MR imaging
window of at least 1 h, allowing the particles (once injected) the
chance to transit to the physiological site of interest in a relevant
timescale for targeted molecular imaging. Furthermore, the
silicon particles, hyperpolarization process, and MRI/MRS in
general are nontoxic and nonradioactive.
1.4 Purpose
We have previously demonstrated proof-of-concept in vivo
imaging of unfunctionalized silicon microparticles in mouse
models,13 as well as for MRI-guided angiocatheter tracking.16
Additional work by other researchers has focused on fundamen-
tal studies11,12,14,15 of the hyperpolarization process in silicon
particles. For this work, our goal was to transition into a new
regime of molecular imaging by functionalizing the silicon
particle surface with a thioaptamer that targets ovarian tumors.
We then studied the effects of particle size (20 nm to 2 μm) and
surface functionalization on the hyperpolarization dynamics.
A variety of relevant particle administration routes in mouse
models were also examined to deduce the ideal method to intro-
duce hyperpolarized silicon particles into mice with different
cancer models. Successful demonstration of long-lasting hyper-
polarized 29Si signal from functionalized particles in vivo is a




Different commercially sourced silicon powders were either
used as received (’unfunctionalized’ or ’bare’), or were coated
in (3-aminopropyl)triethoxysilane (APTES), then cross-linked
with either polyethylene glycol (PEG)—for improved hydrophi-
licity and biocompatibility, or an oligonucleotide aptamer—for
targeting of a specific cancer system (Sec. 3.2). The average
mean diameter of the bare particles ranged in size from
20 nm to 2 μm; the smaller nanoscale particles were mostly
monocrystalline, while larger microparticles were polycrystal-
line/amorphous. For each silicon particle sample, ∼50 to 100 mg
of dry silicon powder was packed into a small Teflon sample
tube (3:2 mm ID × 2 cm length) that is normally used as an
insert for electron spin resonance (ESR) experiments; these
tubes are microwave-invisible and withstand the cryogenic tem-
peratures of DNP.
2.2 Particle Functionalization Protocol
APTES coating: SiNPs are added to 70% ethanol aqueous sol-
ution acidified to pH 2.5 (50 mg particles and 14 ml of solution).
Particles are sonicated for 5 min and then APTES (Sigma-
Aldrich, CAS 919-30-2) is added to the solution to generate
a 150-mM APTES solution. Solution is shaken on a mechanical
rotator overnight. Particles are isolated by centrifugation (5 min,
4000g) and the supernatant is removed. Particles are then
washed three times with ethanol, and then isolated by centrifu-
gation. With the final wash, particles in solution are aliquoted
into preweighed Eppendorf tubes, tubes are centrifuged, super-
natant removed, and the tubes are placed on vacuum centrifuge
to remove any remaining ethanol. Ninhydrin tests of particles
were positive for amines after APTES coating.
Aptamer coupling: For a 200-mg SiNP reaction, 420 mg of
1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, Sigma-
Aldrich, CAS 1892-57-5) was dissolved in 2.1 ml of 50 mM
citrate buffer (pH 5.5) vortexed and put on ice. An amount
of 420 mg of N-hydroxysuccinimide (NHS, Sigma-Aldrich,
CAS 6066-82-6) was dissolved in 2 ml of citrate buffer, vor-
texed, and put on ice. Reagent solutions were made fresh for
each coupling. Combined: a solution of thioaptamer (that targets
the E-Selectin protein) that was synthetically generated to have
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a carboxylic acid tail (169 μM, 1 ml), 250 μl EDC solution, and
250 μl NHS solution. Reaction was allowed to proceed for
15 min at room temperature, and then another 250 μl of both
EDC and NHS solution was added. Reaction was allowed to
go for another 15 min at room temperature. During the NHS-
ester formation reaction, 200 mg of SiNPs were dissolved in
4 ml of borate solution (40 mM, pH 9.25) and sonicated for
5 min. After sonication, the fully activated aptamer solution
was added to the particles, and the reaction was allowed to rotate
on a mechanical rotator for 4 h at room temperature. Solution
was then centrifuged (10 min, 4000g), supernatant removed, and
the particles washed three times with 3 ml of ethanol. After
washes, particles were centrifuged down, supernatant removed,
and particles were stored moist at 4°C.
2.3 Solid-State Dynamic Nuclear Polarization
The sample tube is push-fit onto the end of a G10 fiberglass
rod and inserted into the (laboratory-built) solid-state DNP
device (Fig. 1), which consists of a superconducting magnet
(∼2.9 T), helium flow cryostat (∼3 K), and microwave source
(∼100 mW) that was frequency-modulated from 80.83 to
80.90 GHz to accomodate the relatively wide silicon ESR spec-
trum. The microwaves were directed to the sample tube using a
waveguide and slot antenna. Inside the cryostat, the sample
resides within an in situ NMR coil, allowing quality assurance
using a miniature NMR spectrometer, and next to a resistance
thermocouple (for temperature monitoring). During DNP, the
buildup of 29Si signal was monitored by applying a single
pulse with a small tipping angle at set time points during the
buildup. After sufficient polarization time (1 to 17 h), the sample
tube was quickly removed from the cryostat, warmed to room
temperature, and transported to the MRI scanner suite for im-
aging studies (T transport < 1 min).
2.4 Imaging Protocol
All imaging experiments were performed on a 7 T horizontal-
bore small animal MRI scanner using either a dual-tuned
1H∕29Si litz coil for coregistered imaging (35 mm ID; homo-
geneous rf region ∼52 mm along z-axis; Doty Scientific) or
a dual-coil setup consisting of a laboratory-constructed 29Si sur-
face coil (30 mm) and a commercial 1H volume coil (35 mm ID;
Bruker). A small aliquot (∼1.5 ml) of silicon oil was used for
1H and 29Si sequence calibration purposes; achievable 29Si
nuclear spin polarization values were typically on the order of
∼1%. Spectroscopy (both in the DNP device and the 7 T MRI
scanner) was performed using a simple pulse/acquire sequence.
Imaging studies of solid-state particles, dissolved particles in
phantoms, and in vivo mouse models used a rapid acquisition
with refocused echoes (RARE) sequence. Image reconstruction
and postprocessing were performed in MATLAB®. For dissolu-
tion studies, particles were removed from the sample tube, sus-
pended in warmed phosphate-buffered saline (PBS), and then
administered to the phantom or mouse model via syringe.
2.5 Animal Handling
All animal studies were performed in accordance with the UT
MDAnderson Cancer Center Institutional Animal Care and Use
Committee (IACUC). Mice were placed on an MR-compatible
warming sled and anesthetized with 2% isoflurane (in
0.75 l∕min oxygen) administered via nose cone. Following
hyperpolarization, silicon particles were dissolved/suspended
in PBS and administered to the mice using various delivery
mechanisms, including intraperitoneal injection, oral gavage,
tail vein injection, intratumoral injection, or administered via
the rectum (e.g., enema). Injected mice showed no ill effects
that could be attributed to the presence of the silicon particles
in their system. Mouse models used were (1) normal nude mice
(i.e., control), along with two cohorts of nude mice that received
an orthotopic injection of (2) HeyA8 or (3) SKOV3 ovarian
cancer cell lines. Once the tumor burden became sufficient to
be physically palpable, the mice were used for imaging studies.
3 Results and Discussion
3.1 Effects of Particle Size
A number of different silicon particle sizes were evaluated, rang-
ing from 20 nm to 2 μm average mean diameter. While the
larger microparticles provided greatly enhanced 29Si NMR sig-
nals, the smaller nanoscale particles produced relatively smaller
signal enhancements. However, even with diminished hyperpo-
larization capacity in Si nanoparticles, significant enhancements
were still achieved. Figure 2 compares hyperpolarized 29Si
NMR spectra taken during DNP versus what was available
with the same sample without DNP (i.e., thermal polarization;
inset)—showing an enhancement in 29Si signal by several orders
of magnitude. Additionally, the hyperpolarized signal was
attained in a single scan (<1 s), while the thermal sample
required averaging 16,000 transients to separate the signal from
the noise—taking around 4 days to complete.
The time needed to reach steady-state polarization was
dependent on particle size, due to the nuclear spin diffusion
mechanism that spreads the hyperpolarization from the surface
to the core of the particle. Smaller nanoparticles (<100 nm) only















Fig. 1 Labeled picture of laboratory-constructed solid-state DNP
device for 29Si hyperpolarization. The magnetic field is supplied via
superconducting magnet, while a liquid helium flow cryostat allows
the sample to be held at cryogenic temperatures. The Gunn diode
provides microwaves to transfer polarization from electrons to nearby
nuclei, and the on-board NMR system allows the buildup of 29Si
hyperpolarization to be monitored in real time for dynamics studies
and quality control.
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levels, while larger microparticles needed more than 10 h to
achieve steady-state polarization (Fig. 3). Furthermore, a
dependence on the overall 29Si NMR signal intensity versus
particle size was observed. This dependence was likely due
to: (a) differences in the number and position of electronic
defects as a function of particle size and crystallinity, and/or
(b) differences in surface-to-volume ratio between particle
sizes. Note that polarization is quickly depleted on the surface,
while spins in the particle core are relatively protected, thereby
differentially depleting 29Si polarization in smaller particles to
a greater extent.17
Because of this significant difference in attainable signal
intensities across particle sizes (factor of ∼25×, adjusted for
sample mass), only larger microparticles (2 μm) were studied for
in vivo applications at this time. Current studies are focused on
altering the surface defects of smaller nanoparticles (<100 nm)
using heat and chemical treatments in order to improve DNP
efficiency. Alternatively, a ball mill was applied in an attempt
to break apart the larger microparticles; however, preliminary
studies were hindered by contamination from the ball mill jar
material (stainless steel). Future studies will examine the effects
of using nonferrous jars and balls; even without contamination,
it remains unclear whether the resulting particles will retain a
favorable consistency (and position) of electronic defects, as
well as crystallinity, and with a relevant size/shape distribution.
Because the primary means of depolarization (hence, signal
loss) is through nuclear spin diffusion from the core back to the
surface (provided the lack of internal impurities), the hyperpo-
larization relaxation time also depends on the particle size, with
smaller particles losing the signal enhancement at a faster rate
than larger particles due to the decreased distance from the sur-
face to the core and higher surface-to-volume ratio (Table 1).
In spite of this, even small particles (<100 nm) retain hyper-
polarized signals for ≥10 min, which is still an order-of-
magnitude greater than most other hyperpolarized contrast
agents in vivo.
3.2 Effects of Surface Chemistry
While bare, unfunctionalized silicon microparticles [Fig. 4(a)]
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Fig. 3 Hyperpolarized 29Si polarization buildup curves for (a) 20 nm and (b) 2 μm silicon particles. Silicon
microparticles provide ∼25× more 29Si NMR signal than the nanoscale particles, but take significantly
longer to reach steady-state polarization. Insets: example NMR spectra at relevant time points [(a) 60 min
and (b) 330 min]. Data were collected in real time during DNP process and using on-board NMR system
and a pulse/acquire sequence (100 μs pulse duration; 24.4 MHz). All data were normalized to sample
mass.


























Fig. 2 29Si NMR spectra of 70 nm silicon nanoparticles (56 mg) after
105 min of DNP, showing the ability to hyperpolarize silicon particles
on the nanoscale (single acquisition). Inset: 29Si NMR spectra of the
same sample acquired under thermal equilibrium (room temperature,
without DNP); signal was still ∼300× less than hyperpolarized sample,
even with 16,000 signal averages (100 μs pulse for both instances).
Table 1 29Si polarization decay times (HP T 1) for different silicon
nanoparticle (SiNP) sizes, surface chemistries, and time spent in
the DNP device. Particles of 2 μm size are shown with normal surface
chemistry, as well as the addition of PEG and an ESTA-1 agent that
targets ovarian cancer.
29Si hyperpolarization decay times
SiNP size HP T 1 DNP time
20 nm ∼10 min ∼80 min
30 nm ∼17 min ∼120 min
70 nm ∼16 min ∼60 min
2000 nm ∼62 min ∼300 min
2000-nm PEGylated ∼55 min ∼330 min
2000-nm ESTA-1 ∼56 min ∼300 min
Journal of Medical Imaging 036001-4 Jul–Sep 2016 • Vol. 3(3)
Whiting et al.: Developing hyperpolarized silicon particles for in vivo MRI targeting of ovarian cancer
Downloaded From: https://www.spiedigitallibrary.org/journals/Journal-of-Medical-Imaging on 4/12/2018 Terms of Use: https://www.spiedigitallibrary.org/terms-of-use
to the surface chemistry would greatly increase their utility for
selective targeting and imaging in vivo. Studies were performed
to further develop silicon particles as targeted molecular imag-
ing agents by adding functional groups to the particles’ surface
and testing the effects of these altered surface chemistries on
the hyperpolarization dynamics. Particles were functionalized
with PEG to improve hydrophilicity and biocompatibility;
indeed, the PEGylated particles exhibited improved dissolution
characteristics when compared to bare silicon particles.
Intraperitoneal injection of PEGylated particles into a normal
nude mouse, followed by ∼1 week of wait time, showed particle
accumulation primarily in the liver [Fig. 4(c)] and spleen, with
slight accumulation in the lung, ovary/oviduct, and bone mar-
row. The prevalence of particle accumulation in the liver and
spleen was consistent with the expectation that larger particles
would be taken up by the reticuloendothelial system.
E-selectin thioaptamer (ESTA-1), a monothiophosphate-
modified oligonucleotide aptamer18,19 that binds to E-selectin
—a glycoprotein that is overexpressed on the endothelial cell
surface of certain ovarian cancer tissue—was also conjugated
to the silicon particles [Figs. 4(b) and 4(d)] for molecular target-
ing of ovarian cancer. E-selectin is not present in significant
quantities in normal ovarian tissue, making it a potentially useful
biomarker for ovarian cancer. On their own (unconjugated to the
silicon particles), the thioaptamers20 bind to E-selectin with
nanomolar affinity and are minimally cross-reactive with
other selectins. When conjugated to particles, ESTA-1 has
been demonstrated as safe21 and shown to target breast cancer
metastasis.22,23 They also bind to cultured endothelial cells and
tumor-associated vasculature in murine and human carcinomas.
In addition to the high levels of affinity and specificity, thioap-
tamers are easily synthesized and conjugated to particles, as well
as remaining biocompatible and resistant to nuclease.
These ESTA-1 functionalized particles were tagged with a
fluorescent dye (Cy3) to allow for future cross-correlation
between MRI and optical imaging studies. Importantly, because
29Si DNP uses endogenous electronic defects,14 the addition of
these functional groups to the particle surface did not diminish
the capacity for hyperpolarization buildup or relaxation rates
(Fig. 5). This ability to hyperpolarize aptamer-functionalized
silicon particles was an important step in their progression as
targeted imaging agents. Ongoing and future studies will focus
on administering these ESTA-1 silicon particles into orthotopic
ovarian cancer mouse models to test their ability to function as











Fig. 4 Microscopy images of silicon particles. (a) Representative tun-
neling electron micrograph (TEM) of standard silicon microparticle.
(b) Optical microscopy of silicon microparticles that have been func-
tionalized with ESTA-1 and Cy3 dye, showing successful coupling of
functional groups to silicon particles. (c) Nuclear fast red staining of
cells from an excised mouse liver—silicon microparticles previously
administered to the alive mouse via intraperitoneal injection 1 week
prior; green arrows denote some of the silicon microparticles (black
dots). (d) TEM of a ∼70 nm silicon nanoparticle functionalized with
ESTA-1, appearing as the transluscent layer on the particle surface.
(a)






















































Fig. 5 Plots of hyperpolarized 29Si NMR signal (normalized by sample mass) buildup (a) and decay
(b) for samples with different surface chemistries: “Bare” particles (black squares), as well as those
with added PEG (blue triangles) and ESTA-1 (red circles) functionalities coupled to the particle surface.
Inset: HP T 1 values for the three particle types, calculated from decay rates in (b). *Bare data taken 2
months after other data; during that time the Q of the NMR coil drifted, contributing to the lower overall
signal of the “Bare” data (but without affecting the buildup/decay rates). Hyperpolarization buildup and
decay rates very similar across datasets; slight increase in buildup rate for ESTA-1 particles and slightly
longer T 1 for bare particles noticed.
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3.3 Initial Imaging Studies
Following DNP, the sample can be efficiently transferred to
the small animal MRI scanner while retaining sufficient hyper-
polarized signal to allow 29Si imaging experiments. Compared
to previous studies13 at a different location using the same exper-
imental parameters, the 7-T scanner in this study provides nearly
an order-of-magnitude improvement in signal-to-noise ratio due
to newer hardware and improved electromagnetic shielding
properties. Because the benefits of the hyperpolarization process
are field-independent, the increase in field strength between
studies (4.7 → 7 T) was largely inconsequential for 29Si MRI
(but improved 1H anatomical imaging). Initial imaging scans
using the silicon particles in their sample tube as a phantom
reveal that the signal was still observable 30 min after comple-
tion of the DNP process (Fig. 6). Most other biomedically
relevant HP imaging agents have much shorter hyperpolarized
relaxation times under ambient conditions (e.g., HP T1 of
13C-pyruvate ∼1 min).8 This longer relaxation time will
allow the silicon particles to accumulate at their targeted site
in vivo in a timeframe relevant for molecular imaging.
3.4 Silicon Particle Administration Routes
Following the successful phantom imaging, we performed
proof-of-concept studies in mouse models to demonstrate the
long-lasting hyperpolarized 29Si signal. In addition to targeting
ovarian cancer, hyperpolarized silicon particles can be consid-
ered as a “platform technology,” where different disease systems
can be interrogated in real time by adding a variety of targeting
groups to the particle surface. Because different cancer systems
arise (and are orthotopically modeled) at dissimilar locations
throughout the body, and the optimal delivery of the targeted
particles is needed to maximize the chances of success, a variety
of particle dissolution/suspension and administration methods
were tested in mouse models. It was found that the (manual)
dissolution process works optimally in the fringe field of the
7-T MRI scanner, where the field is strong (compared to
Earth’s field) and the chance of hyperpolarization-depleting
zero-field crossing is minimized. The particles were adminis-
tered to the mouse models in a variety of ways; these include
injecting into the intraperitoneal (IP) cavity, tail vein, adminis-
tering to the large intestines via the rectum (i.e., enema), as well
as through oral gavage.
Tail vein injection, which is the most common method of
intravascular administration of MR contrast agents to mouse
models, could not be used for the 2-μm sized particles due to
their large size and relative insolubility, despite PEGylation.
Injected particles would travel ∼1 cm up the tail vein before
stopping due to a blockage or clog. Also, the viscosity and pro-
pensity for aggregation of the microparticle suspension requires
the use of a larger needle, which is not conducive to tail vein
injections. Future use of smaller nanoscale silicon particles may
enable the revaluation of this administration route for in vivo
studies.
The alternative administration routes were more successful,
and in vivo hyperpolarized 29Si imaging were achieved using
PEGylated silicon microparticles. Oral gavage, which can be
used to study diseases of the upper gastrointestinal tract, was
difficult to administer in a timely fashion using a soft plastic
oral gavage needle (due to proximity to MRI scanner) and
while keeping the mouse stationed on the sled. However, we
were able to acquire 29Si images of the particles inside the stom-
ach using this method [Fig. 7(a)]. Injections into the rectum (via
the anus), to study diseases of the large intestines, were achieved
(a) (b) (c)
t =0 min t =30 min
Fig. 6 Initial 29Si MR image of silicon particles packed inside sample
tube. (a) Image acquired using a 10 deg RARE sequence immediately
after 4 h of DNP. (b) Image acquired using a 90 deg RARE sequence
30 min after (a). (c) Photo of silicon particles in sample tube/phantom
(particle region: 2 cm long; 3.2 mm internal diameter). 137 mg of unfunc-
tionalized 2 μm silicon particles (dry powder) were used for this study.
TR/TE: 1 s∕1.761 ms; RARE factor ¼ 32; imaging resolution ¼ 2 mm;

















































Fig. 7 In vivo 29Si MRI for 2 μm silicon particles. (a) Administration of
∼135 mg of PEGylated silicon particles (in 300 μl PBS) into a normal
mouse via oral gavage, followed by a 5-min wait prior to imaging.
(b) Administration of ∼135 mg of PEGylated silicon particles (in 1 ml
PBS) via injection through the rectum of a normal mouse using a soft
plastic gavage needle (3.8 mm diameter), followed by a 5-min wait
prior to imaging. (c) Administration of ∼100 mg of PEGylated silicon
particles (in 300 μl PBS) via intraperitoneal injection into a normal
mouse, followed by a 30-min wait prior to imaging; gravitational
settling is noted at the injection site. (d) Administration of ∼135 mg
of ESTA-1 functionalized silicon particles (in 600 μl PBS) into a
SKOV3 mouse via intraperitoneal injection, followed by physical
manipulation of the mouse’s abdomen to help distribute the particles,
then a 10-min wait prior to imaging. 29Si imaging scans (color): 90 deg
RARE imaging sequence, TR/TE: 59.9∕1.8 ms, FOV: 64 × 64 mm,
resolution: 2 mm; single scan acquisition (scan time ∼ 60 ms), proc-
essed with 35% threshold to filter background. Coregistered with 1H
imaging scans (grayscale): 90 deg RARE imaging sequence, coronal
plane, TR/TE: 1800∕9.5 ms, FOV: 64 × 64 mm; resolution: 0.25 mm;
three averages (scan time ∼ 3 min).
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through insertion of a soft, flexible applicator needle or small
diameter (∼1∕8 in:) rubber tube [Fig. 7(b)]. This method
kept the particle concentration per voxel high (as the particles
are contained in the defined volume of the intestines), leading to
increased 29Si signal. The success of this method was improved
when it was used after the administration of a saline enema
(Fleet) at least 30 min prior to particle insertion. Additional
gains may be achieved when implementing dietary restrictions
and laxatives the night prior to the scan. Fecal blockages can be
problematic with this administration route, but silicon particles
delivered in this fashion have been imaged in the large intestines
from the rectum to the cecum. Ongoing work includes improv-
ing multislice 29Si imaging sequences that will help differentiate
the three-dimensional folding of the intestinal tract.
IP injections of hyperpolarized microparticles [Fig. 7(c)],
which can be used for targeting orthotopic ovarian cancer,
displayed sufficient 29Si signal postinjection. However, the
majority of the 29Si signal was concentrated at the injection
site, meaning that the large microparticles did not disperse
throughout the cavity. Postinjection physical manipulation
(e.g., massage) of the mouse’s abdomen [Fig. 7(d)] resulted
in spatial movement of the 29Si signal, but it is not considered
active targeting. It is likely that the large size of the micropar-
ticles prevents them from actively transiting throughout the IP
cavity; instead, they gravitationally settle at the injection site.
Ongoing studies are attempting to use fluid distension of the
IP cavity to encourage dispersion; additional studies will use
smaller 29Si nanoparticles for in vivo studies.
3.5 Initial Work in Tumor Models
Preliminary targeted studies in small animals utilized a HeyA8
orthotopic ovarian cancer mouse model with the ESTA-1 func-
tionalized silicon microparticles. Because of the difficulties with
particle movement following intraperitoneal injection, these
functionalized particles were directly injected into the tumor
mass in 3 to 4 injections throughout the tumor volume. The
hyperpolarized 29Si MRI signal was still present 20 min after
injection (Fig. 8) and was predominately located within the
tumor region. While this cannot be considered targeted imaging,
the long-lasting 29Si signal inside the tumor boundary was an
encouraging finding that will prompt future targeted imaging
studies. The further development of sufficiently hyperpolarized
nanoscale silicon particles should exhibit improved mobility and
allow for true targeted imaging.
3.6 Potential for Prospective Clinical Translation
Given their biocompatibility and the nontoxic, nonionizing
nature of both MRI and hyperpolarization, there is expected
to be a low barrier to eventual clinical translation of HP silicon
particles for MRI applications. The 29Si precession frequency is
observable on most multinuclear MRI scanners; however, com-
panies will need to develop and test suitable clinical-scale 29Si
MR coils and optimize imaging sequences to efficiently use the
long-lasting, enhanced signal. Dosing and toxicity studies will
be required, and will likely benefit from a current clinical trial5
that examines the role of silicon particles as drug delivery agents
for treating pancreatic cancer. Also, the recent push of different
hyperpolarized modalities into the clinic9 may simplify many of
the initial burdens of introducing a new HP contrast agent into
human studies. In addition to targeting ovarian cancer, ESTA-1
functionalized silicon particles may be used for molecular
imaging of other cancer systems that overexpress E-Selectin—
including breast, prostate, colorectal, and pancreatic cancers.24
Furthermore, silicon particles may also be developed as a plat-
form technology to interrogate a number of disease systems
(through conjugation of additional targeting moieties) for
multiplexed diagnostics. Given the very long hyperpolarized
relaxation times and ability to perform molecular targeting
(as opposed to metabolic tracing), silicon particles have the
potential to bridge the gap between hyperpolarized imaging
and nanomedicine.
4 Conclusions
In this work, we demonstrate the hyperpolarization of a variety
of different silicon particle sizes and surface chemistries. The
larger microparticles provided the highest signal enhancements
over the longest time durations, likely due to their polycrystal-
line/amorphous structure and smaller surface-to-volume ratio
when compared to smaller particles. The addition of targeting
groups to the particles’ surface did not alter the hyperpolarization
dynamics, as the free electrons necessary for DNP were endog-
enous to the particles. High field MR imaging was accomplished
using phantoms and mouse models via a variety of particle ad-
ministration methods. These results represent encouraging find-
ings for applying hyperpolarized silicon particles as noninvasive
molecular imaging agents. However, work is still needed;
ongoing studies involve developing small, more physiologically
relevant nanoparticles for in vivo imaging and continuing with
the targeted imaging studies in orthotopic mouse models.
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